Natco Pharma up 3% on launching generic Posaconazole injection in India

This is the first time an injection version of this drug available in India.

Shares of Natco Pharma rose 3.6 percent intraday Monday as the company has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand POSANAT.

This is the first time an injection version of this drug available in India.

Share Market Tips
POSANAT will be available in 18 .0 mg/ml strength, a formulation for intravenous (IV) use. Posaconazole Injection is sold in the USA market by Merck under its brand name of NOXAFIL.

Posaconazole injection is an antifungal agent & used in patients who are at high risk of developing infections due to being severely immunocompromised, such as associated with stem cell transplant or from chemotherapy.

At 09:39 hrs Natco Pharma was quoting at Rs 798.65, up Rs 11.90, or 1.51 percent on the BSE.

Two days Free Trial and best services packages for dealing in Stock market click here to get >> Stock Market Tips By Ripples Advisory Give a Missed call @9644405056

Comments

Popular posts from this blog

Daily equity Market By Ripplesadvisory Report 16-Aug-2016

सकारात्मक वैश्विक रुझानों के सहारे बाजार में मजबूती, निफ्टी 10,900 के ऊपर

11-year data suggests bears control D-Street in September; can bulls defy odds?